Lake Street Capital Increases Alphatec (NASDAQ:ATEC) Price Target to $20.00

Alphatec (NASDAQ:ATECGet Rating) had its price objective increased by equities researchers at Lake Street Capital from $16.50 to $20.00 in a research note issued on Thursday, The Fly reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Lake Street Capital’s target price indicates a potential upside of 52.32% from the company’s current price.

A number of other equities research analysts have also issued reports on ATEC. Needham & Company LLC increased their price target on Alphatec from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 4th. Jefferies Financial Group began coverage on Alphatec in a research note on Wednesday, October 12th. They issued a “buy” rating and a $12.00 price target for the company. StockNews.com began coverage on Alphatec in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Finally, Morgan Stanley increased their price target on Alphatec from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, January 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $15.64.

Alphatec Trading Up 3.5 %

NASDAQ:ATEC opened at $13.13 on Thursday. The company has a debt-to-equity ratio of 29.74, a current ratio of 2.14 and a quick ratio of 1.33. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.53 and a beta of 1.31. Alphatec has a one year low of $5.73 and a one year high of $13.65. The business has a fifty day moving average price of $10.71 and a 200-day moving average price of $9.16.

Alphatec (NASDAQ:ATECGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Alphatec had a negative return on equity of 575.45% and a negative net margin of 49.34%. The company had revenue of $89.84 million during the quarter, compared to analysts’ expectations of $87.07 million. Sell-side analysts forecast that Alphatec will post -1.44 EPS for the current year.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP David Sponsel sold 10,000 shares of the stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $9.88, for a total transaction of $98,800.00. Following the completion of the transaction, the executive vice president now owns 556,983 shares of the company’s stock, valued at approximately $5,502,992.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director James L. L. Tullis sold 50,000 shares of the stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $10.59, for a total value of $529,500.00. Following the completion of the transaction, the director now owns 497,974 shares of the company’s stock, valued at approximately $5,273,544.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 10,000 shares of the stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $9.88, for a total transaction of $98,800.00. Following the completion of the transaction, the executive vice president now directly owns 556,983 shares of the company’s stock, valued at approximately $5,502,992.04. The disclosure for this sale can be found here. Insiders sold 70,000 shares of company stock valued at $720,800 in the last 90 days. Insiders own 33.93% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ATEC. Quantamental Technologies LLC raised its position in Alphatec by 8.0% in the 3rd quarter. Quantamental Technologies LLC now owns 13,170 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 980 shares during the period. CIBC Private Wealth Group LLC raised its position in Alphatec by 8.4% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 12,904 shares of the medical technology company’s stock worth $113,000 after purchasing an additional 1,000 shares during the period. Captrust Financial Advisors raised its position in Alphatec by 5.2% in the 2nd quarter. Captrust Financial Advisors now owns 23,712 shares of the medical technology company’s stock worth $155,000 after purchasing an additional 1,162 shares during the period. Arizona State Retirement System raised its position in Alphatec by 8.0% in the 2nd quarter. Arizona State Retirement System now owns 18,836 shares of the medical technology company’s stock worth $123,000 after purchasing an additional 1,390 shares during the period. Finally, Credit Suisse AG raised its position in Alphatec by 3.7% in the 3rd quarter. Credit Suisse AG now owns 51,705 shares of the medical technology company’s stock worth $452,000 after purchasing an additional 1,846 shares during the period. Institutional investors own 48.59% of the company’s stock.

Alphatec Company Profile

(Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Featured Articles

The Fly logo

Analyst Recommendations for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.